XML 18 R12.htm IDEA: XBRL DOCUMENT
v3.26.1

License and Collaboration Agreements | 6 Months Ended
--- | ---
Jun. 30, 2026
License And Collaboration Agreements [Abstract] |
License and Collaboration Agreements | (5) License and Collaboration Agreements Genrix License Agreement In June 2025, the Company and Chongqing Genrix Biopharmaceutical Co., Ltd. (“Genrix”) entered into a license agreement (the “Genrix License Agreement”), pursuant to which Genrix granted Cullinan a global (excluding mainland China, Hong Kong, Macau and Taiwan), exclusive license to develop and commercialize velinotamig, a BCMAxCD3 T cell engager, in all fields of use. Under the terms of the Genrix License Agreement, Cullinan paid Genrix an upfront license fee of $20.0 million. Genrix will be eligible to receive up to $292.0 million in milestone payments based on the achievement of development and regulatory milestones. Genrix is also eligible to receive up to an additional $400.0 million in net sales-based milestones as well as tiered royalties ranging from mid-single digit to mid-teens, as a percentage of net sales of licensed products. Unless earlier terminated, the Genrix License Agreement will continue in effect on a country-by-country basis until the expiration of Cullinan’s royalty obligations in such country. The Genrix License Agreement may be terminated by either party for a material breach by the other party, subject to notice and cure provisions, or in the event of the other party’s insolvency. Additionally, subject to a notice period, Cullinan may terminate the Genrix License Agreement for convenience. In the Genrix License Agreement, each party made customary representations and warranties and agreed to customary covenants, including, without limitation, with respect to indemnification, for transactions of this type. Cullinan evaluated the Genrix License Agreement and determined that the exclusive license to develop and commercialize velinotamig represented an asset acquisition of in-process research and development. The Company also determined that the asset had no alternative future use at the time of acquisition, and therefore, the upfront license fee of $20.0 million was recorded within research and development expenses in June 2025. As of June 30, 2026, no milestone obligations have been incurred under the Genrix License Agreement. Taiho Agreements Cullinan has a co-development agreement with an affiliate of Taiho Pharmaceutical Co., Ltd ("Taiho"), pursuant to which the Company is collaborating to develop zipalertinib for the treatment of a genetically defined subset of patients with non-small cell lung cancer (“NSCLC”), and Taiho will commercialize zipalertinib. For the agreed-upon indication, Taiho and Cullinan share development costs equally, and each party will receive 50% of any future pre-tax profits from potential U.S. sales of zipalertinib, subject to certain adjustments. For any additional indications that Taiho chooses to develop independently, Taiho will bear all development costs until it has sufficient data from such indication to support a commercial purpose or submission of zipalertinib for such indication. At such time, 50% of Taiho’s independent development costs, subject to certain adjustments, will be deducted from future pre-tax profits for potential U.S. sales of zipalertinib. In November 2025, Taiho independently initiated an ongoing global Phase 3 clinical trial evaluating zipalertinib in an additional indication. The Company concluded that the co-development agreement with Taiho is a collaborative arrangement because Cullinan is an active participant in both the development of zipalertinib and the oversight of commercialization for zipalertinib. Amounts due to or from Taiho for zipalertinib development activities after the execution of the co-development agreement are recorded within research and development expenses or general and administrative expenses based on the nature of the activity. The following table summarizes each party’s respective share of costs incurred and paid by the other party for zipalertinib development activities for the three and six months ended June 30, 2026 and 2025 (in thousands):
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2026 |  |  | 2025 |  |  | 2026 |  |  | 2025 |
Cullinan's share of zipalertinib research and development costs incurred by Taiho |  | $ | 6,618 |  |  | $ | 7,772 |  |  | $ | 12,428 |  |  | $ | 13,390 |
Cullinan’s share of general and administrative costs incurred by Taiho |  | $ | 1,005 |  |  | $ | 592 |  |  | $ | 1,671 |  |  | $ | 1,064 |
Taiho’s share of research and development costs incurred by Cullinan |  | $ | 652 |  |  | $ | 3,112 |  |  | $ | 1,474 |  |  | $ | 4,486 |
Under a separate agreement, Cullinan is also eligible to receive up to $130.0 million from Taiho tied to epidermal growth factor receptor exon 20 non-small cell lung cancer U.S. regulatory milestones. As of June 30, 2026, no milestone payments have been received under this agreement. Other License and Collaboration Agreements The Company has certain payment obligations that are contingent upon future events under various other license and collaboration agreements. Under these agreements, Cullinan will be required to make milestone payments upon successful completion and achievement of certain intellectual property, clinical, regulatory, and sales milestones and will be required to make royalty payments in connection with the sale of products developed under these agreements. During each of the three and six months ended June 30, 2026 and 2025, no milestone obligations were incurred under the Company’s other license and collaboration agreements.

X
- Definition License and collaboration agreements. + References No definition available. + Details
Name: | cgem_LicenseAndCollaborationAgreementsAbstract
Namespace Prefix: | cgem_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition License and collaboration agreements. + References No definition available. + Details
Name: | cgem_LicenseAndCollaborationAgreementsTextBlock
Namespace Prefix: | cgem_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration